

FAST FACTS

WF 1802 - INFLUENCE OF PRIMARY TREATMENT FOR PROSTATE CANCER ON WORK EXPERIENCE (PCW)

Inclusion Criteria

1. Male diagnosed with adenocarcinoma of the prostate, stage I, II, or III. Patient may have already received hormonal therapy or expect to receive hormonal therapy as treatment for adenocarcinoma of the prostate
2. Scheduled to undergo prostatectomy or initiate radiation for primary curative treatment of adenocarcinoma of the prostate within 90 days of enrollment
3. Self-identify as African American/Black, non-Hispanic OR white, non-Hispanic; Participants are considered African American for recruitment purposes if they (1) identify solely as African American for race OR (2) identify as African American and white for race, but do not identify as also being of another race. Participants are considered white for recruitment purposes if they select white and no other race. (These identities are based on participant self-report during the screening process.)
4. ECOG score = 0 or 1
5. Worked within the past 14 days prior to screening (no minimum number of hours required) OR (a) worked at some point between March 1, 2020- March 14, 2020 and (b) subsequently lost job involuntarily due to COVID-19.
6. Intends to be working 6 months from screening (if opportunity to work is available pending the COVID-19 pandemic considerations)
7. Patient is willing to provide answers on the Patient Eligibility Questionnaire regarding household income.
8. Age at time of screening is ≥ 18
9. Can speak and understand spoken English
10. Ability to understand an informed consent document (even if only verbally) and willingness to agree to informed consent
11. Access to telephone or willingness to travel to NCORP site for each of the three interviewer-administered Structured Questionnaires
12. Able to hear sufficiently to understand a conversation determined by a simple test given at screening
13. Has not previously had a prostatectomy, radiation therapy, or chemotherapy to treat adenocarcinoma of the prostate.
14. Not expected (at time of screening) to receive chemotherapy for primary treatment of adenocarcinoma of the prostate

Exclusion Criteria

1. Patient has received therapy for any other cancer within last 3 years (except for non-melanoma skin cancer).
2. Patient plans to receive therapy for any other cancer within the next year (except for non-melanoma skin cancer).

SCHEMA

INFLUENCE OF PRIMARY TREATMENT FOR PROSTATE CANCER ON WORK EXPERIENCE

Study Population:

African American/Black OR White, Non-Hispanic; diagnosed with adenocarcinoma of the prostate, stages I, II, or III; anticipated initiation of primary, curative treatment for adenocarcinoma of the prostate (e.g., prostatectomy or radiation) within 90 days of enrollment and employed within 14 days prior to enrollment (or meets modified inclusion criteria due to post-COVID-19 impact on US employment).



Stratification: 55 eligible participants will be recruited in each of the following 3 strata:

- African American, non-Hispanic men with < 300% poverty level
- African American, non-Hispanic men with ≥ 300% poverty level
- White, non-Hispanic men with < 300% poverty level

90 will be enrolled in the 4th and final strata (54 were enrolled before March 1, 2020 with an additional 36 to be recruited March 1, 2020 or after) to allow for possible fluctuations in work status due to the COVID-19 pandemic in all stratum:

- White, non-Hispanic men with ≥ 300% poverty level

**Baseline:**

Data collection of work ability measures and completion of Structured Interviewer Questionnaires within 90 days prior to start of initiation of primary, curative treatment

**3 Months after completion of treatment (+/- 14 days):**

Collection of work ability measures and Structured Interviewer Questionnaires

**6 Months after completion of treatment (+/- 21 days):**

Collection of work ability measures and Structured Interviewer Questionnaires

**Endpoints:****Primary:**

Change in work ability measured by the Global Work Ability measure from Baseline to 6 Months after treatment completion

Secondary:

- (1) Trajectory of change in work ability at Baseline to 3 and 6 months after treatment completion, as measured by Global Work Ability.
- (2) Trajectory of change in work ability at Baseline to 3 and 6 months after treatment completion, as measured by WLQ and employment status

Wake Forest NCORP Research Base

Version Date: 06/22/2021

WF-1802
Page 5 of 43

- (3) Differences between preferred and actual length of leave at 3 and 6 months after treatment completion

Study Sample: 255 participants